ESR1 and triple-negative breast carcinoma: Among molecular subtypes based on protein expression status, triple-negative breast cancer (TNBC), i.e., lack of expression in estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), accounts for up to 15% of breast cancer cases [1].